Literature DB >> 3500381

A study of potential vestibulotoxic effects of once daily versus thrice daily administration of tobramycin.

L Proctor1, B Petty, R Thakor, P Lietman, R Glackin, H Shimizu.   

Abstract

Tobramycin 5.1 mg/kg/day was administered for 9 days to 20 healthy human volunteers to determine the potential vestibulotoxicity of once daily versus thrice daily treatment regimens. Vestibular function was tested carefully before, during, and following drug administration, using a battery of postural and caloric tests. Although subjects receiving the once daily regimen performed better on the postural tests, we feel this does not necessarily indicate an adverse effect in either group. The caloric test was the primary measure of vestibular function in this experiment, and this test appeared to demonstrate a slight adverse effect during drug administration of equal magnitude in both treatment groups. The results of this experiment indicate that there is no significant difference in the risk of adverse vestibular effects between once daily and thrice daily tobramycin administration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3500381     DOI: 10.1288/00005537-198712000-00012

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  7 in total

Review 1.  Aminoglycoside-induced hearing loss in humans.

Authors:  R E Brummett; K E Fox
Journal:  Antimicrob Agents Chemother       Date:  1989-06       Impact factor: 5.191

Review 2.  Once-daily aminoglycoside therapy.

Authors:  D N Gilbert
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Once-daily dosing of aminoglycosides.

Authors:  J Blaser; C König
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-12       Impact factor: 3.267

4.  Effect of gentamicin dosing interval on therapy of viridans streptococcal experimental endocarditis with gentamicin plus penicillin.

Authors:  J Gavaldà; A Pahissa; B Almirante; M Laguarda; E Crespo; L Pou; F Fernández
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

Review 5.  What is the evidence for once-daily aminoglycoside therapy?

Authors:  M L Barclay; E J Begg; K G Hickling
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

6.  Adaptive resistance following single doses of gentamicin in a dynamic in vitro model.

Authors:  M L Barclay; E J Begg; S T Chambers
Journal:  Antimicrob Agents Chemother       Date:  1992-09       Impact factor: 5.191

7.  The Incidence of Amikacin Ototoxicity in Multidrug-ResistantTuberculosis Patients.

Authors:  Mohammad Reza Javadi; Bahareh Abtahi; Kheirollah Gholami; Behzad Safari Moghadam; Payam Tabarsi; Jamshid Salamzadeh
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.